# Nine-Year Surveillance of Candida Bloodstream Infections in a Southern Italian Tertiary Hospital: Species Distribution, Antifungal Resistance, and Stewardship Implications

**Authors:** Anna Maria Spera, Veronica Folliero, Chiara D’Amore, Biagio Santella, Flora Salzano, Tiziana Ascione, Federica Dell’Annunziata, Enrica Serretiello, Gianluigi Franci, Pasquale Pagliano

PMC · DOI: 10.3390/jpm16010017 · Journal of Personalized Medicine · 2026-01-02

## TL;DR

A nine-year study in a southern Italian hospital tracked Candida bloodstream infections, finding rising resistance and the importance of tailored treatment strategies.

## Contribution

The study provides detailed local epidemiological data on Candida species distribution and antifungal resistance trends over nine years in a tertiary hospital.

## Key findings

- Candida albicans was the most common species, but non-albicans species like C. parapsilosis showed increasing resistance.
- Fluconazole, voriconazole, and amphotericin B resistance rates rose among C. albicans and other species.
- Medical wards had the highest incidence, with patients averaging 76 years old.

## Abstract

Purpose: Candida bloodstream infections remain a major global health challenge, with mortality rates approaching 40%. Beyond classical immunocompromised status, recent evidence highlights additional risk factors, including iatrogenic immunosuppression, advanced age, prolonged hospitalization, exposure to broad-spectrum antibiotics, and total parenteral nutrition. While Candida albicans (C. albicans) remains the most common species in Europe and the USA, non-albicans species, particularly Nakaseomyces glabratus (N. glabratus), Candida tropicalis (C. tropicalis), and Candida parapsilosis (C. parapsilosis), are emerging worldwide. Methods: This retrospective observational cohort study was conducted at the University Hospital “San Giovanni di Dio e Ruggi d’Aragona” in Salerno, Italy, from January 2015 to December 2024. It included all patients with at least one positive blood culture for Candida species. Demographic data, hospital ward of admission, and antifungal susceptibility profiles were collected and analyzed using SPSS software (IBM SPSS Statistics for Mac, version 30 (IBM Corp., Armonk, NY, USA)). Results: The incidence rate is 48.7 new isolates per one thousand patient-days, with a trend of increasing episodes over time among a total of 364 patients. Most cases occurred in medical wards (59.5%), where patients were older (median age 76 (17). C. albicans accounted for 57.9% of isolates, and a significant association was found between species distribution and hospital unit (p < 0.05). Resistance to fluconazole, voriconazole, and amphotericin B increased among C. albicans, with similar trends in N. glabratus and C. parapsilosis. Conclusions: This large single-center cohort highlights both the persistent dominance of C. albicans and the worrisome rise in resistance among C. parapsilosis. Given the aging patient population and increasing antifungal resistance, local epidemiological data are crucial to guide empirical therapy. Our findings underscore the need for multidisciplinary antifungal stewardship programs to optimize personalized treatment strategies and contain the emergence of resistant strains.

## Linked entities

- **Chemicals:** fluconazole (PubChem CID 3365), voriconazole (PubChem CID 71616), amphotericin B (PubChem CID 1972)
- **Species:** Candida albicans (taxon 5476), Nakaseomyces glabratus (taxon 5478), Candida tropicalis (taxon 5482)

## Full-text entities

- **Diseases:** Candida Bloodstream Infections (MESH:D018805), C. parapsilosis (OMIM:211750)
- **Chemicals:** voriconazole (MESH:D065819), amphotericin B (MESH:D000666), fluconazole (MESH:D015725)
- **Species:** Candida tropicalis (species) [taxon 5482], Homo sapiens (human, species) [taxon 9606], Candida albicans (species) [taxon 5476], Lodderomyces parapsilosis (species) [taxon 5480]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12843064/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12843064/full.md

## References

30 references — full list in the complete paper: https://tomesphere.com/paper/PMC12843064/full.md

---
Source: https://tomesphere.com/paper/PMC12843064